Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon in Bi-hormonal Artificial Pancreas for T1D
NCT05454709Phase 2Withdrawn
- Sponsor
- Inreda Diabetic
- Start
- Dec 2023
- Primary completion
- Dec 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dasiglucagon in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Inreda Diabetic. Primary endpoint: Time in Range (3.9 - 10.0 mmol/l) at 3 days. Planned start Dec 2023; status: withdrawn.
02
Drugs
dasiglucagon
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05454709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05454709.